Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.

<h4>Objective</h4>Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection. Multiple studies have compared efficacy and safety of these two agents, but yielded inconsistent results. Hence, we conducted a meta-anal...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Weixia Ke, Li Liu, Chi Zhang, Xiaohua Ye, Yanhui Gao, Shudong Zhou, Yi Yang
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/9e0cb0f2aece45ca8518ab7aecb9b011
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9e0cb0f2aece45ca8518ab7aecb9b011
record_format	dspace
spelling	oai:doaj.org-article:9e0cb0f2aece45ca8518ab7aecb9b0112021-11-18T08:16:42ZComparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.1932-620310.1371/journal.pone.0098865https://doaj.org/article/9e0cb0f2aece45ca8518ab7aecb9b0112014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24905092/pdf/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objective</h4>Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection. Multiple studies have compared efficacy and safety of these two agents, but yielded inconsistent results. Hence, we conducted a meta-analysis to discern comparative efficacy and safety.<h4>Methods</h4>Published data relevant to a comparison of TDF and ETV used in HBV were included. HBV DNA suppression rate, ALT normalization rate, and HBeAg seroconversion rate at 24 weeks and 48 weeks were reviewed. Drug safety profiles and resistance were also discussed.<h4>Results</h4>Seven articles met entry criteria. Four and six articles included data for 24 and 48-week HBV DNA suppression rates, respectively, and no significant differences for the rates between the two drugs were found in chronic HBV patients (TDF vs. ETV: relative risk [RR] = 1.10, 95% CI = 0.91-1.33 and RR = 1.07, 95% CI = 0.99-1.17 for 24 weeks and 48 weeks, respectively). For the ALT normalization rate (three studies for 24 weeks, four articles for 48 weeks) and HBeAg seroconversion rate (two and four studies for 24 weeks and 48 weeks, respectively), no difference was observed between TDF and ETV. Additionally, no significant distinction in short term safety was found for CHB patients.<h4>Conclusions</h4>TDF and ETV are similarly effective and safe in chronic HBV patients after 24 weeks and 48 weeks of anti-viral therapy. Nevertheless, the long-term efficacy and safety of TDF and ETV should be monitored in prolonged therapy.Weixia KeLi LiuChi ZhangXiaohua YeYanhui GaoShudong ZhouYi YangPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 6, p e98865 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Weixia Ke Li Liu Chi Zhang Xiaohua Ye Yanhui Gao Shudong Zhou Yi Yang Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
description	<h4>Objective</h4>Tenofovir (TDF) and entecavir (ETV) are both potent antiviral agents for the treatment of chronic hepatitis B virus (HBV) infection. Multiple studies have compared efficacy and safety of these two agents, but yielded inconsistent results. Hence, we conducted a meta-analysis to discern comparative efficacy and safety.<h4>Methods</h4>Published data relevant to a comparison of TDF and ETV used in HBV were included. HBV DNA suppression rate, ALT normalization rate, and HBeAg seroconversion rate at 24 weeks and 48 weeks were reviewed. Drug safety profiles and resistance were also discussed.<h4>Results</h4>Seven articles met entry criteria. Four and six articles included data for 24 and 48-week HBV DNA suppression rates, respectively, and no significant differences for the rates between the two drugs were found in chronic HBV patients (TDF vs. ETV: relative risk [RR] = 1.10, 95% CI = 0.91-1.33 and RR = 1.07, 95% CI = 0.99-1.17 for 24 weeks and 48 weeks, respectively). For the ALT normalization rate (three studies for 24 weeks, four articles for 48 weeks) and HBeAg seroconversion rate (two and four studies for 24 weeks and 48 weeks, respectively), no difference was observed between TDF and ETV. Additionally, no significant distinction in short term safety was found for CHB patients.<h4>Conclusions</h4>TDF and ETV are similarly effective and safe in chronic HBV patients after 24 weeks and 48 weeks of anti-viral therapy. Nevertheless, the long-term efficacy and safety of TDF and ETV should be monitored in prolonged therapy.
format	article
author	Weixia Ke Li Liu Chi Zhang Xiaohua Ye Yanhui Gao Shudong Zhou Yi Yang
author_facet	Weixia Ke Li Liu Chi Zhang Xiaohua Ye Yanhui Gao Shudong Zhou Yi Yang
author_sort	Weixia Ke
title	Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
title_short	Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
title_full	Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
title_fullStr	Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
title_full_unstemmed	Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.
title_sort	comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis b virus infection: a systematic review and meta-analysis.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/9e0cb0f2aece45ca8518ab7aecb9b011
work_keys_str_mv	AT weixiake comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis AT liliu comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis AT chizhang comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis AT xiaohuaye comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis AT yanhuigao comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis AT shudongzhou comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis AT yiyang comparisonofefficacyandsafetyoftenofovirandentecavirinchronichepatitisbvirusinfectionasystematicreviewandmetaanalysis
_version_	1718422000811114496

Comparison of efficacy and safety of tenofovir and entecavir in chronic hepatitis B virus infection: a systematic review and meta-analysis.

Ejemplares similares